Reaction

Abdominal Mass reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,639 reports · 80 co-occurring drugs

As of the last recalculation, Abdominal Mass appears in 2,639 FAERS reports alongside 80 co-occurring drug terms. The strongest observed disproportionality signal is VEDOLIZUMAB (PRR 19.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Vedolizumab	194	19.1	19.1
Octreotide Acetate	66	17.4	17.4
Rabeprazole	45	16.3	16.3
Doxepin	17	13.3	13.3
Doxepin Hydrochloride	18	11.3	11.3
Niraparib	31	11.1	11.1
Erythromycin	25	10.6	10.6
Lanreotide Acetate	10	10.1	10.1
Dimenhydrinate	13	9.7	9.7
Ifosfamide	25	9.3	9.3
Interferon Beta-1B	20	8.3	8.3
Dalteparin Sodium	11	8.2	8.2
Filgrastim	37	7.9	7.9
Erythropoietin	20	7.7	7.7
Human Immunoglobulin G	20	7.7	7.7
Standardized Senna Concentrate	12	7.6	7.6
Iron Sucrose	9	7.5	7.5
Enoxaparin Sodium	53	7.4	7.4
Polatuzumab Vedotin	9	7.3	7.3
Cholestyramine	11	7.2	7.2
Imatinib Mesylate	25	7.1	7.1
Ursosiol	17	6.9	6.9
Zinc	21	6.8	6.8
Zinc Chloride	21	6.7	6.7
Infliximab-Dyyb	24	6.5	6.5
Loperamide Hydrochloride And Dimethicone	26	6.4	6.5
Zinc Gluconate	21	6.4	6.4
Azithromycin	32	6.3	6.3
Azithromycin Monohydrate	33	6.3	6.3
Ursodiol	17	6.2	6.2
Anastrozole Tablets	16	5.9	5.9
Fondaparinux Sodium	6	5.9	5.9
Doxorubicin Hydrochloride	24	5.8	5.8
Vincristine Sulfate	21	5.7	5.7
Mesalamine	40	5.7	5.7
Bendamustine Hcl	11	5.6	5.6
Adalimumab-Adaz	37	5.6	5.6
Regorafenib	8	5.4	5.5
Hydroxyzine Hydrochloride	9	5.4	5.4
Hydroxyzine Hydrochloride Oral	9	5.4	5.4
Rucaparib	6	5.4	5.4
Obinutuzumab	11	5.3	5.3
Pyrazinamide	6	5.0	5.0
Mesna Injection	5	4.8	4.8
Teduglutide	8	4.7	4.7
Mesna	5	4.7	4.7
Gemcitabine	23	4.6	4.6
Acalabrutinib	7	4.6	4.6
Metoclopramide	31	4.5	4.5
Sitagliptin And Metformin Hydrochloride	12	4.4	4.4
Isoniazid	9	4.4	4.4
Ibrutinib	44	4.4	4.4
Cytarabine	32	4.2	4.2
Cisplatin	40	4.1	4.1
Gemcitabine Hydrochloride	27	4.0	4.0
Venetoclax	31	4.0	4.0
Axicabtagene Ciloleucel	5	4.0	4.0
Etoposide	36	3.9	3.9
Doxorubicin	43	3.9	3.9
Olaparib	10	3.8	3.8
Oxaliplatin	35	3.8	3.8
Sunitinib Malate	18	3.6	3.6
Gefitinib	4	3.5	3.5
Sorafenib	9	3.4	3.4
Temozolomide	8	3.0	3.0
Trametinib	9	2.9	2.9
Siponimod	3	2.7	2.7
Fentanyl Citrate	6	2.7	2.7
Bendamustine Hydrochloride	4	2.6	2.6
Dabrafenib	7	2.6	2.6
Avapritinib	4	2.6	2.6
Panitumumab	5	2.5	2.5
Pazopanib Hydrochloride	8	2.3	2.3
Exenatide	15	2.3	2.3
Paricalcitol	4	2.2	2.2
Patiromer	3	1.7	1.7
Abaloparatide	6	1.6	1.6
Dulaglutide	17	1.5	1.5
Copper	8	1.5	1.5
Erenumab-Aooe	7	1.0	1.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.